Retatrutide 5mg

Retatrutide (LY3437943) is a novel investigational triple agonist peptide that simultaneously targets three key metabolic receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This tripartite mechanism of action distinguishes it from existing dual or single agonist compounds and has generated considerable interest within metabolic disease research.

In preclinical and early clinical studies, retatrutide has demonstrated pronounced effects on energy homeostasis, insulin secretion, glucose regulation, and body weight modulation. By co-activating GLP-1 and GIP receptors, the compound supports glycaemic control and insulinotropic signalling, whilst glucagon receptor agonism is believed to contribute to increased energy expenditure and hepatic glucose output modulation. This combination may offer complementary and synergistic effects across multiple metabolic pathways.

Each vial contains 5mg of retatrutide as a lyophilised powder with a purity of >98% as determined by HPLC analysis. Molecular formula: C₂₂₄H₃₅₆N₅₈O₆₈S₂. Molecular weight: approximately 4963.5 g/mol. CAS number: 2381090-43-1. Store lyophilised peptide at -20°C, protected from light and moisture. Once reconstituted, store at 4°C and use within 28 days.

For research purposes only. Not for human use.